

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

FOZARD ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/01227

FILED: 7 FEBRUARY 2003

U.S. APPLICATION NO: NOT YET KNOWN

35 USC §371 DATE: HERewith

FOR: USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN
FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed with the entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/01227, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-2614


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: July 14, 2004

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PA/4-32352A
APPLICATION NO.**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

APPLICANT
FOZARD ET AL.
FILING DATE

Group

DT15 Rec'd PCT/PTO 14 JUL 2004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,929,067	7/27/99	Gerspacher et al.	514	212	8/21/97
	AB	6,319,917	11/20/01	Gerspacher et al.	514	212	9/5/00
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	02/051440	7/4/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Callahan, "Irritable Bowel Syndrome Neuropharmacology. A Review of Approved and Investigational Compounds", Journal of Clinical Gastroenterology, Vol. 35, No. 1 Suppl., pp. S58-S67 (2002).
	AS	Gerspacher et al., "Dual Neurokinin NK1/NK2 antagonists: N-'(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)..." Bioorganic & Medicinal Chemistry Letters, Vol. 11, No. 23, pp. 3081-3084 (2001).
	AT	Renzi et al., "Substance P (neurokinin-1) and Neurokinin A (neurokinin-2) Receptor Gene and Protein Expression in the Healthy and Inflamed Human Intestine", American Journal of Pathology, Vol. 157, No. 5, pp. 1511-1522 (2000).
	AU	Tough et al., "Dual and Selective Antagonism of Neurokinin NK(1) and NK(2) Receptor-Mediated Responses in Human Colon Mucosa", Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 367, No. 2, pp. 104-108 (2003).

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.